Dificid (fidaxomicin) / Merck (MSD), Astellas 
Welcome,         Profile    Billing    Logout  
 11 Diseases   2 Trials   2 Trials   1263 News 


«12...567891011121314151617»
  • ||||||||||  vancomycin / Generic mfg., Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
    Clinical, Review, Journal:  Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. (Pubmed Central) -  Oct 3, 2020   
    Actoxumab (MAb against C. difficile toxin A; CDA1) plus bezlotoxumab (MAb against C. difficile toxin B; CDB1) in combination or bezlotoxumab alone appeared to be more effective in preventing rCDI compared to actoxumab alone...Several CDI-specific antibiotics, FMT modalities, monoclonal antibodies, and various prebiotics and probiotics demonstrated a reduction in risk of rCDI with the greatest risk reduction observed with FMT and monoclonal antibody therapy. It is notable that the comparators in these studies were very different from one another and the relative risk reduction of rCDI may not be directly comparable from one study to the next.
  • ||||||||||  tacrolimus / Generic mfg., sirolimus / Generic mfg.
    [VIRTUAL] Not Your Typical Diarrhea: A Case of Disseminated MAC in a Solid Organ Transplant Recipient () -  Sep 15, 2020 - Abstract #ACG2020ACG_1223;    
    She was recently discharged after a prolonged hospital stay for management of acute diarrhea and was diagnosed with recurrent Clostridium difficile Infection (CDI) that required multiple courses of fidaxomicin as she was intolerant to vancomycin...Her immunosuppressive regimen included mycophenolic acid, sirolimus, prednisone, and tacrolimus with therapeutic range drug levels...Patient was started antimicrobial therapy with ethambutol, rifampin, and azithromycin guided by infectious disease specialist with resolution of diarrhea and weight gain...The causes of diarrhea are exhaustive in patients on immunosuppression and hence it is important to keep MAC in the differential as its diagnosis is challenging and requires tissue sampling with culture and gene sequencing. Antimicrobials provide effective treatment and eradication.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    [VIRTUAL] Fidaxomicin Use for Clostridium difficile Infection Decreases the Effect of Coumadin in Elderly () -  Sep 15, 2020 - Abstract #ACG2020ACG_1085;    
    Alternate regimen such as the prolonged pulse taper of Vancomycin should be used for the C.diff recurrences. There is only one article about this interaction in the literature and as Gastroenterologists increase the use of this drug to treat C.Diff infection, further studies need to be done to confirm this interaction to prevent catastrophic complications in the elderly with subtherapeutic INR.
  • ||||||||||  vancomycin / Generic mfg., Dificid (fidaxomicin) / Merck (MSD), Astellas
    Clinical, Review, Journal:  Management of Clostridioides difficile infection in patients with inflammatory bowel disease. (Pubmed Central) -  Aug 19, 2020   
    Microbiota restoration therapies are effective to prevent recurrent CDI in IBD patients. This review summarizes the epidemiology, pathophysiology, diagnostic testing, outcomes and management of both CDI and IBD, in CDI complicating IBD.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Clinical, Review, Journal:  Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin. (Pubmed Central) -  Jul 9, 2020   
    This article reviews the most recent advances, including the elucidation of a unique mode of action by cryo-EM structures, and the efforts towards the clarification of the biosynthetic pathway. Moreover, known fidaxomicin analogs and their reported antibacterial activities are summarized.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    [VIRTUAL] RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_4009;    
    We conclude that in our experience risk of early CDI infection after HSCT was increased by pre-trasplant factors such as previous gram negative bacterial infections and prior abdominal surgery and by the choice of mismatched unrelated donor. Stool negativity was obtained in all patients with appropriate treatment and there was no increased risk of GvHD or OS impairment, suggesting that search for CDI at the first episode of diarrhea after HSCT and prompt treatment can definitively solve this infection without sequelae in allogeneic HSCT recipients.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    [VIRTUAL] RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_4008;    
    We conclude that in our experience risk of early CDI infection after HSCT was increased by pre-trasplant factors such as previous gram negative bacterial infections and prior abdominal surgery and by the choice of mismatched unrelated donor. Stool negativity was obtained in all patients with appropriate treatment and there was no increased risk of GvHD or OS impairment, suggesting that search for CDI at the first episode of diarrhea after HSCT and prompt treatment can definitively solve this infection without sequelae in allogeneic HSCT recipients.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    [VIRTUAL] RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_4007;    
    We conclude that in our experience risk of early CDI infection after HSCT was increased by pre-trasplant factors such as previous gram negative bacterial infections and prior abdominal surgery and by the choice of mismatched unrelated donor. Stool negativity was obtained in all patients with appropriate treatment and there was no increased risk of GvHD or OS impairment, suggesting that search for CDI at the first episode of diarrhea after HSCT and prompt treatment can definitively solve this infection without sequelae in allogeneic HSCT recipients.
  • ||||||||||  Flagyl (metronidazole) / SLA
    [VIRTUAL] An intervention bundle to improve compliance with clinical guidelines for Clostridioides difficile infection: a quasi- experimental study () -  May 22, 2020 - Abstract #ECCMID2020ECCMID_5793;    
    The intervention led to an increase in the use of oral vancomycin (50.6% [87/172] vs. 34.5% [79/231]; P-value<0.001) and fidaxomicin (3.5% [6/172] vs. 0% [0/231]; P-value<0.001) and a decrease in the use of oral metronidazole (36% [62/172] vs. 54.5% [126/231]; P-value=0.0014) and intravenous metronidazole (7.6% [13/172] vs. 23.8% [55/231]; P-value=0.005). A bundle of evidence-based measures for patients diagnosed with a first episode of CDI provided a better compliance with clinical practice guidelines and might reduce the rate of relapses.
  • ||||||||||  Clinical, Journal:  Clostridium Difficile Infection in Patients Impact Suspected Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease. (Pubmed Central) -  May 16, 2020   
    Of the 14 IBD patients with CDI, 8 patients (57.1%) were receiving anti-tumor necrosis factor (anti-TNF) therapy (21.4 % infliximab or golimumab, 7.1% vedolizumab or adalimumab) and 43.5% of patients were being treated with systemic corticosteroids...Among them, 1 patient (7.1%) had recurrent CDI after 5 months from the first episode of CDI.These patients were treated with vancomycin, metronidazole and fidaxomicin...Immunosuppressive medications and older age are associated with increased risk of CDI and poor outcome. Although, CMV is a rare colonic pathogen in the immunocompetent patient, it should be included and screened when exacerbation of IBD occurs in patients receiving any type of immunosuppressive therapy.
  • ||||||||||  Flagyl (metronidazole) / SLA
    Journal:  Clostridioides difficile Infection: Update on Management. (Pubmed Central) -  May 9, 2020   
    Metronidazole is no longer recommended as first-line therapy for adults...In routine or endemic settings, hands should be cleaned with either soap and water or an alcohol-based product, but during outbreaks soap and water is superior. The Infectious Diseases Society of America does not recommend the use of probiotics for prevention of C. difficile infection.
  • ||||||||||  Flagyl (metronidazole) / SLA
    Review, Journal:  Updated Management Guidelines for Clostridioides difficile in Paediatrics. (Pubmed Central) -  Apr 23, 2020   
    Fidaxomicin is a new treatment option with equivalent initial response rates as vancomycin but lower relapse rates of CDI...Monoclonal antibodies and vaccines seem to represent a future perspective against CDI. However, only further studies will permit us to understand whether these new approaches could be effective in therapy and prevention of CDI in paediatric populations.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, NN1213 / Novo Nordisk
    Enrollment closed:  OpTION: Optimal Treatment for Recurrent Clostridium Difficile (clinicaltrials.gov) -  Apr 7, 2020   
    P4,  N=546, Active, not recruiting, 
    Whether co-existence of the two above-mentioned distinct clinical entities is just a co-incidence or CDI is a triggering factor for IgA vasculitis remains to be elucidated in future large-scale studies. Recruiting --> Active, not recruiting